Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Open accessThe DOI matches its Crossref record; 187 of the 187 references it cites were found in a registry or an index.
Abstract
Mood disorders are common, chronic, recurrent mental illnesses that affect the lives of millions of individuals worldwide. To date, the monoaminergic systems (serotonergic, noradrenergic and dopaminergic) in the brain have received the greatest attention in neurobiological studies of mood disorders, and most therapeutics target these systems. However, there is growing evidence that the glutamatergic system is central to the neurobiology and treatment of these disorders. Here, we review data supporting the involvement of the glutamatergic system in mood-disorder pathophysiology as well as the efficacy of glutamatergic agents in mood disorders. We also discuss exciting new prospects for the development of improved therapeutics for these devastating disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This could lead to astrocyte/microglia imbalance, glutamatergic overproduction and excitotoxic neuronal damage (Sanacora et al., 2008) with impact on synapse functionality.”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, increased glutamate levels has been associated with mechanisms involved in stress and depression, such as neuro-inflammatory process, decreased levels of neurotrophic factors, diminished neurogenesis, and neuroplasticity impairment [116,117].”
From P2X7 Receptor Signaling in Stress and Depression (2019) · cites this paper as [117]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, rapidly acting antidepressants were discovered in the glutamatergic system (Berman et al., 2000;Sanacora et al., 2008).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Several classes of antidepressants as well as SSRIs are known to exert action on the glutamate system by influencing NMDA or AMPA receptor transcription (Sanacora et al., 2008).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Glia also play an important role in regulating the synthesis and reuptake of glutamate and thereby influence synaptic function and morphology16,17.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“Although most patients with mood disorders receive some benefit from available treatment”
BackgroundTrivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Self-citationA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationEvidence-based health policy—lessons from the Global Burden of Disease Study
Murray, C. J. L., & Lopez, A. D. (1996) · Science · doi:10.1126/science.274.5288.740 · Cited by 2,178
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043 · cited 1×
“, and is approved for the treatment of moderate to severe Alzheimer's disease, in which it has been shown to enhance cognition and minimize clinical deterioration in patients with Alzheimer's disease, vascular dementia or mixed dementi”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Research works printed but not linked: 1
- Preskorn, S. et al. A placebo-controlled trial of the NR2B subunit specific NMDA antagonist CP-101,606 plus paroxetine for treatment resistant depression (TRD). Annual Conference of the American Psychological Association (San Francisco, California) 154 (2007).
Cited by
Items 501–600 of 1,000
Maraone, A., Tarsitani, L., Pinucci, I., & Pasquini, M. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i9.568 · Cited by 15
The roles of neuroinflammation and glutamatergic excitotoxicity in treatment-resistant depression
Candee, R., Wilkenson, R., Schreiber, M., & DeCenzo, M. (2023) · JAAPA · doi:10.1097/01.jaa.0000921252.57819.4b · Cited by 20
Ohashi, M., Saitoh, A., Yamada, M., Oka, J.-I., & Yamada, M. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3676-1 · Cited by 20
Chitty, K. M., Lagopoulos, J., Hickie, I. B., & Hermens, D. F. (2014) · Clinical Neurophysiology · doi:10.1016/j.clinph.2014.09.025 · Cited by 20
Prefrontal cortex glutamate and extraversion
Grimm, S., Schubert, F., Jaedke, M., Gallinat, J., & Bajbouj, M. (2011) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsr056 · Cited by 20
Hodgson, K., Mufti, S., Uher, R., & McGuffin, P. (2012) · Genome Medicine · doi:10.1186/gm351 · Cited by 20
Ferensztajn‐Rochowiak, E., Kaczmarek, M., Wójcicka, M., Kaufman-Szukalska, E., Dziuda, S., Remlinger-Molenda, A., Szeliga-Neymann, A., Losy, J., & RYBAKOWSKI, J. K. (2018) · Neuropsychobiology · doi:10.1159/000493740 · Cited by 20
Gobert, A., Rivet, J., Billiras, R., Parsons, F., & Millan, M. J. (2011) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2011.08.040 · Cited by 20
Zang, X., Zhang, J., Hu, J., Mo, X., Zheng, T., Ji, J., Xing, J., Chen, C., & Zhou, S. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.08.123 · Cited by 19
The effects of intermittent theta burst stimulation (iTBS) on resting-state brain entropy (BEN)
Liu, P., Song, D., Deng, X., Shang, Y., Ge, Q., Wang, Z., & Zhang, H. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00556 · Cited by 19
Management of obsessive-compulsive disorder comorbid with bipolar disorder
Kazhungil, F., & Mohandas, E. (2016) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.192001 · Cited by 19
Entorhinal cortex-based metabolic profiling of chronic restraint stress mice model of depression
Chen, X., Lan, T., Wang, Y., He, Y., Wu, Z., Tian, Y., Li, Y., Bai, M., Zhou, W., Zhang, H., et al. (2020) · Aging · doi:10.18632/aging.102798 · Cited by 19
p11 and Gene Therapy for Severe Psychiatric Disorders: A Practical Goal?
Chen, G., Twyman, R. E., & Manji, H. K. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001754 · Cited by 19
Self-citationRéus, G. Z., Abaleira, H. M., Michels, M., Tomaz, D. B., dos Santos, M. A. B., Carlessi, A. S., Matias, B. I., Leffa, D. D., Damiani, A. P., Gomes, V. D. C., et al. (2014) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2014.12.005 · Cited by 19
Ludka, F. K., Tandler, L. D. F., Kuminek, G., Olescowicz, G., Jacobsen, J., & Molz, S. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000211 · Cited by 19
From Renewable Levulinic Acid to a Diversity of 3‐(Azol‐3‐yl)Propanoates
Flores, A. F. C., Piovesan, L. A., Pizzuti, L., Flores, D. C., Malavolta, J. L., & Martins, M. A. P. (2013) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.1774 · Cited by 19
Fan, L., Zhao, C., Fu, W., Xu, N., Liu, J., Lü, A., Li, Z., Su, S.-Y., Wu, T., & Ou, A. (2016) · Journal of Acupuncture and Meridian Studies · doi:10.1016/j.jams.2016.04.002 · Cited by 19
Citti, C., Battisti, U. M., Cannazza, G., Jóźwiak, K., Stasiak, N., Puja, G., Ravazzini, F., Ciccarella, G., Braghiroli, D., Parenti, C., et al. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00257 · Cited by 19
Research progress on vesicle cycle and neurological disorders
Zhang, C., Zhu, L., & Chen, C. (2021) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps31458 · Cited by 18
Li, X., Jing, K., Lu, H., Li, K., Zhang, Y., & Hasichaolu, H. (2022) · BioMed Research International · doi:10.1155/2022/6334868 · Cited by 18
Ito, T., Yoshida, M., Aida, T., Kushima, I., Hiramatsu, Y., Ono, M., Yoshimi, A., Tanaka, K., Ozaki, N., & Noda, Y. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15790 · Cited by 18
Budni, J., Molz, S., Dal-Cim, T. A., Martin‐de‐Saavedra, M. D., Egea, J., López, M. G., Tasca, C. I., & Rodrigues, A. L. S. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0425-6 · Cited by 18
Zhang⋆, Y., Luo, Y., Zhang, D., Pang, B., Wen, J., & Zhou, T. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.625108 · Cited by 18
Vallée, A., Vallée, J.-N., & Lecarpentier, Y. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01329-3 · Cited by 18
Stan, T. L., Sousa, V. C., Zhang, X., Ono, M., & Svenningsson, P. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.07.007 · Cited by 18
Anderson, I. M., Blamire, A. M., Branton, T., Brigadoi, S., Clark, R. A., Downey, D., Dunn, G., Easton, A., Elliott, R., Elwell, C. E., et al. (2017) · Efficacy and Mechanism Evaluation · doi:10.3310/eme04020 · Cited by 18
Hasegawa, S., Yoshimi, A., Mouri, A., Uchida, Y., Hida, H., Mishina, M., Yamada, K., Ozaki, N., Nabeshima, T., & Noda, Y. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.12.020 · Cited by 18
Rapid Antidepressant Activity of Ketamine Beyond NMDA Receptor
Hashimoto, K. (2017) · Springer eBooks · doi:10.1007/978-3-319-49795-2_4 · Cited by 17
Glutamatergic dysregulation in mood disorders: opportunities for the discovery of novel drug targets
Panek, M., Kawalec, P., Malinowska‐Lipień, I., Brzostek, T., & Pilc, A. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1836160 · Cited by 17
Khan, M. I., Nikoui, V., Naveed, A., Mumtaz, F., Zaman, H., Haider, A., Aman, W., Wahab, A., Khan, S. N., Ullah, N., et al. (2021) · Alcohol · doi:10.1016/j.alcohol.2021.01.005 · Cited by 17
Insulin and disorders of behavioural flexibility
Sullivan, M., Fernández‐Aranda, F., Camacho‐Barcia, L., Harkin, A., Macrì, S., Mora‐Maltas, B., Jiménez‐Múrcia, S., O’Leary, A., Ottomana, A. M., Presta, M., et al. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105169 · Cited by 17
Freitas, A. E., Moretti, M., Budni, J., Balen, G. O., Fernandes, S. C. P., Veronezi, P. O., Heller, M., Micke, G. A., Pizzolatti, M. G., & Rodrigues, A. L. S. (2013) · Journal of Medicinal Food · doi:10.1089/jmf.2012.0276 · Cited by 17
Synaptic Stress and Pathogenesis of Neuropsychiatric Disorders
Popoli, M., Diamond, D., & Sanacora, G. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1056-4 · Cited by 17
Self-citationDagher, M., Cahill, C. M., & Andrews, A. M. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100046 · Cited by 16
Mood Disorders are Associated With Increased Risk of BPPV: A National Sample Cohort
Kim, S. K., Hong, S. M., Park, I., Lee, H., Park, B., & Choi, H. G. (2020) · The Laryngoscope · doi:10.1002/lary.28638 · Cited by 16
Lithium and Atypical Antipsychotics: The Possible WNT/β Pathway Target in Glaucoma
Vallée, A., Vallée, J.-N., & Lecarpentier, Y. (2021) · Biomedicines · doi:10.3390/biomedicines9050473 · Cited by 16
Yonezawa, K., Uchida, H., Yatomi, T., Ohtani, Y., Nomoto‐Takahashi, K., Nakajima, S., Mimura, M., & Tani, H. (2023) · Pharmacopsychiatry · doi:10.1055/a-2179-8884 · Cited by 16
Retour aux sources: defining the structural basis of glutamate receptor activation
Dawe, G. B., Aurousseau, M. R. P., Daniels, B. A., & Bowie, D. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2014.277921 · Cited by 16
Getting the balance right: Established and emerging therapies for major depressive disorders
Vezmar (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s10485 · Cited by 16
Trevithick, L., McAllister-Williams, H., Blamire, A. M., Branton, T., Clark, R. A., Downey, D., Dunn, G., Easton, A., Elliott, R., Ellwell, C., et al. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0641-4 · Cited by 16
Fornaro, M., Kardash, L., Novello, S., Fusco, A., Anastasia, A., Berardis, D. D., Perna, G., & Carta, M. G. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1428554 · Cited by 16
Frizzo, M. E. (2019) · Current Therapeutic Research · doi:10.1016/j.curtheres.2019.100566 · Cited by 16
Frank, D., Gruenbaum, B. F., Shelef, I., Zvenigorodsky, V., Севериновська, О. В., Gal, R., Dubilеt, M., Zlotnik, A. A., Kofman, O., & Boyko, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.832478 · Cited by 16
Bakhla, A. K., Gore, P., & Srivastava, S. (2013) · Industrial Psychiatry Journal · doi:10.4103/0972-6748.123636 · Cited by 16
Magnesium and ketamine in the treatment of depression.
Górska, N., Słupski, J., Szałach, Ł. P., Włodarczyk, A., Szarmach, J., Jakuszkowiak‐Wojten, K., Gałuszko‐Węgielnik, M., Wilkowska, A., Wiglusz, M. S., & Cubała, W. J. (2019) · PubMed · Cited by 16
di Michele, F., Talamo, A., Niolu, C., & Siracusano, A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200406090051 · Cited by 16
Jiang, Y., Dong, Y., & Hu, H. (2024) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2023.0225 · Cited by 15
Luo, W. F., Fang, M., Xu, H., Xing, H., & Nie, Q. (2015) · Animal Genetics · doi:10.1111/age.12325 · Cited by 15
Doose, A., Tam, F. I., Hellerhoff, I., King, J. A., Boehm, I., Gottloeber, K., Wahl, H., Werner, A., Raschke, F., Bartnik‐Olson, B., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02580-6 · Cited by 15
Mahmoudi, E., Faizi, M., Hajiaghaee, R., & Razmi, A. (2018) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.22127/rjp.2018.58486 · Cited by 15
Brambilla, C. R., Veselinović, T., Rajkumar, R., Mauler, J., Matusch, A., Ruch, A., Orth, L., Ramkiran, S., Sbaihat, H., Kaulen, N., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-021-01763-3 · Cited by 15
A Review of MR Spectroscopy Studies of Pediatric Bipolar Disorder
Kondo, D. G., Hellem, T., Shi, X., Sung, Y. H., Prescot, A. P., Kim, T.-E., Huber, R. S., Forrest, L. N., & Renshaw, P. F. (2014) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3844 · Cited by 15
de Mello, L. R., Hamley, I. W., Miranda, A., Alves, W. A., & da Silva, E. R. (2019) · Journal of Peptide Science · doi:10.1002/psc.3170 · Cited by 15
Drugs with glutamate-based mechanisms of action in psychiatry
Chrobak, A. A., & Siwek, M. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00656-8 · Cited by 14
Changes in kinetics of amino acid uptake at the ageing ovine blood–cerebrospinal fluid barrier
Chen, R. L., & Preston, J. E. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.01.015 · Cited by 14
Are mGluR2/3 Inhibitors Potential Compounds for Novel Antidepressants?
Yajie, J., Zou, M., Ren, T., & Wang, Y. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-022-01310-8 · Cited by 14
Ward, S. E., Beswick, P., Calcinaghi, N., Dawson, L. A., Gartlon, J. E., Graziani, F., Jones, D. N. C., Lacroix, L. P., Mok, M. H. S., Oliosi, B., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13696 · Cited by 14
Changes in brain Glx in depressed bipolar patients treated with lamotrigine: A proton MRS study
Godlewska, B. R., Emir, U. E., Masaki, C., Bargiotas, T., & Cowen, P. J. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.12.092 · Cited by 14
Wang, W., Zhou, T., Rong, J., Zhang, H., Zhang, Y., Wang, C., Dong, Y., Wang, J., Li, S., Wu, H., et al. (2019) · Bioscience Reports · doi:10.1042/bsr20190524 · Cited by 14
Paroxetine loaded PLGA nanoparticles
Sharma, S., & Dang, S. (2020) · Materials Today Proceedings · doi:10.1016/j.matpr.2020.01.568 · Cited by 14
Bansal, Y., Fee, C., Misquitta, K. A., Codeluppi-Arrowsmith, S. A., Sibille, E. L., Berman, R., Coric, V., Sanacora, G., & Banasr, M. (2023) · Complex Psychiatry · doi:10.1159/000529534 · Cited by 14
Self-citation6‐Sulfatoxymelatonin as a predictor of clinical outcome in depressive patients
Hidalgo, M. P. L., Caumo, W., Dantas, G., Franco, D. G., Torres, I. L. D. S., Pezzi, J. C., Elisabetsky, E., Detanico, B. C., Piato, Â., & Markus, R. P. (2011) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1204 · Cited by 14
Karolewicz, B., Çetin, M., & Arıcıoğlu, F. (2011) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5350/kpb-bcp201121101 · Cited by 14
Kumar, G., Au, N. P. B., Lei, E. N.-Y., Mak, Y. L., Chan, L. L. H., Lam, M. H., Chan, L. L., Lam, P. K. S., & Ma, C. H. E. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0093-y · Cited by 14
Horváth, H. R., Fazekas, C. L., Balázsfi, D., Jain, S. K., Haller, J., & Zelena, D. (2017) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-017-0528-7 · Cited by 14
McArthur, R. A., & Borsini, F. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00032-1 · Cited by 14
Fernández-Pereira, C., & Agís‐Balboa, R. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062561 · Cited by 13
Zhang, J., Niu, Z., Wang, T., Yu, L., Ren, X., Zhang, S., Zhu, Y., & Qi, D. (2025) · Perioperative Medicine · doi:10.1186/s13741-025-00567-z · Cited by 13
Wang, X., Cheng, M., Su, Y., Zhang, C., & Meng, X. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac083 · Cited by 13
Čolić, L., Demenescu, L. R., Li, M., Kaufmann, J., Krause, A. L., Metzger, C., & Walter, M. (2015) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsv110 · Cited by 13
Pesarico, A. P., Stangherlin, E. C., Rosa, S. G., Mantovani, A. C., Zeni, G. R., & Nogueira, C. W. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.04.046 · Cited by 13
McColm, J., Brittain, C., SURIYAPPERUMA, S., Swanson, S., Tauscher‐Wisniewski, S., Foster, J., Soon, D., & Jackson, K. A. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13252 · Cited by 13
Lee, K., Park, C., Oh, Y., Lee, H., & Cho, J. (2018) · Molecules · doi:10.3390/molecules23030669 · Cited by 13
Peters, E. M., Bowen, R., & Balbuena, L. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000947 · Cited by 13
Jacobs, A., Hagin, M., Shugol, M., Shomron, N., Pillar, N., Fañanás, L., Serretti, A., Vieta, E., & Popović, D. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.03.009 · Cited by 13
Watanabe, M., Marcy, B., Kinoshita, K., Fukasawa, M., Hikichi, H., Chaki, S., Okuyama, S., Gevorkyan, H., & Yoshida, S. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14331 · Cited by 13
Emerging role of glutamate in the pathophysiology and therapeutics of Gulf War illness
Wang, X., Ali, N., & Lin, C. G. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119609 · Cited by 13
Ruppa, K. B. P., King, D., & Olson, R. E. (2012) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-396492-2.00007-2 · Cited by 13
Irvine, M. W., Fang, G., Sapkota, K., Burnell, E. S., Volianskis, A., Costa, B. M., Culley, G. R., Collingridge, G. L., Monaghan, D. T., & Jane, D. E. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.054 · Cited by 13
Capitão, L. P., Forsyth, J., Thomaidou, M. A., Condon, M. D., Harmer, C. J., & Burnet, P. W. J. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120908904 · Cited by 13
Xiong, X., Poulsen, M. H., Hussein, R. A., Nørager, N. G., & Strømgaard, K. (2014) · ChemMedChem · doi:10.1002/cmdc.201402278 · Cited by 13
Sanacora, G. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0780 · Cited by 13
Self-citationWang, J., Li, W., Li, M., Wu, H.-B., & Qiu, Z.-K. (2023) · Medicine · doi:10.1097/md.0000000000034670 · Cited by 12
Zha, T., Fang, X., Wan, J., Chen, X., Lin, J., & Chen, Q. (2025) · Biomolecules · doi:10.3390/biom15020165 · Cited by 12
Effects of N-acetylcysteine and imipramine in a model of acute rhythm disruption in BALB/c mice
Pilz, L. K., dos Santos, Y. T., Quiles, C. L., Benvenutti, R., de Melo, G. M., Levandovski, R. M., Hidalgo, M. P. L., & Elisabetsky, E. (2014) · Chronobiology International · doi:10.3109/07420528.2014.965315 · Cited by 12
Role of group II metabotropic glutamate receptors in ketamine's antidepressant actions
Onisiforou, A., Georgiou, P., & Zanos, P. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173531 · Cited by 12
León, B. E., Peyton, L., Essa, H., Wieden, T., Marion, N., Childers, W. E., Abou-Gharbia, M. A., & Choi, D. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109515 · Cited by 12
Zhang, B., Su, D., Song, Y., Li, H., Chen, C., Liao, L., Zhang, H., Luo, J., Yang, M., Zhu, G., et al. (2023) · Fitoterapia · doi:10.1016/j.fitote.2023.105583 · Cited by 12
Yao, H., Wang, X., Chi, J., Chen, H., Liu, Y., Jiayi, Y., Yu, J., Ruan, Y., Xiang, X., Pi, J., et al. (2024) · Molecules · doi:10.3390/molecules29050964 · Cited by 12
Music therapy for depression: A narrative review
Wang, X., Huang, W., Liu, S., He, C., Wu, H. Y., Cheng, L., & Deng, S. (2024) · Brain‐X · doi:10.1002/brx2.72 · Cited by 12
Alò, R., Mele, M., Fazzari, G., Avolio, E., & Canonaco, M. (2015) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2015.09.007 · Cited by 12
O'Toole, E., Doucet, M. V., Sherwin, E., & Harkin, A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802456-0.00003-0 · Cited by 12
Chitty, K. M., Lagopoulos, J., Kaur, M., Hickie, I. B., & Hermens, D. F. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu113 · Cited by 12
Mueller, R. W., Rachwał, S., Varney, M. A., Johnson, S. A., Kashinatham, A., Zhong, S., Li, Y., Haroldsen, P. E., Herbst, T., & Street, L. J. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.09.132 · Cited by 12
Ketamine a dissociative anesthetic: Neurobiology and biomolecular exploration in depression
Liu, G.-L., Cui, Y., Lu, C., & Zhao, P. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109006 · Cited by 12
N-Substituted pyrrolidines and tetrahydrofurans as novel AMPAR positive modulators
Thewlis, K. M., Aldegheri, L., Harries, M. H., Mookherjee, C., Oliosi, B., & Ward, S. E. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.09.062 · Cited by 12
Cruceanu, C., López, J. P., Tsai, W. J., & Turecki, G. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.138 · Cited by 12
Acupuncture Treatment for Social Defeat Stress
Kawanokuchi, J., Takagi, K., Tanahashi, N., Yamamoto, T., Nagaoka, N., Ishida, T., & Ma, N. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.685433 · Cited by 11
L-Cysteine: A promising nutritional supplement for alleviating anxiety disorders
Liu, R., Song, D., Zhang, Y., Gong, H., Jin, Y., Wang, X., Jiang, Y., Yan, Y.-X., Lu, B.-N., Wu, Y., et al. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.07.038 · Cited by 11
Li, F., Xie, L., Xiao, Q., Li, J., Zhong, H., Xu, X., Tu, J., & Luo, Q. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.176215 · Cited by 11
Metadata
- Authors
- Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K.
- Affiliations
- Yale University (US)
- National Institutes of Health (US)
- Corresponding author
- Manji, Husseini K.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2008-05
- Volume
- 7
- Issue
- 5
- Pages
- 426-437
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC2715836
- OpenAlex
- W2074907255
- Cited by
- 894
- References
- 186
- Citations by year
- 2026: 17 · 2025: 29 · 2024: 33 · 2023: 44 · 2022: 36 · 2021: 44 · 2020: 56 · 2019: 43 · 2018: 40 · 2017: 50 · 2016: 63 · 2015: 70 · 2014: 59 · 2013: 56 · 2012: 68
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (K02MH076222, Z01MH002828, Z01MH002857)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- glutamatergic system, mood disorders, antidepressants, neuroplasticity, glutamatergic agents, monoaminergic systems, rapid-acting antidepressants, drug development
- MeSH terms
- Animals, Glutamates, Humans, Psychotropic Drugs, Excitatory Amino Acid Antagonists, Mood Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.